Last reviewed · How we verify
SYN023
SYN023 is a monoclonal antibody targeting the PD-1 receptor.
SYN023 is a monoclonal antibody targeting the PD-1 receptor. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.
At a glance
| Generic name | SYN023 |
|---|---|
| Also known as | Zamerovimab and Mazorelvimab Injection, A Humanized Anti-Rabies Molecular antibodies cocktails |
| Sponsor | Synermore Biologics Co., Ltd. |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By binding to PD-1, SYN023 prevents the interaction between PD-1 and its ligands, leading to the activation of T cells and enhanced anti-tumor immune response.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
- Head and neck squamous cell carcinoma
Common side effects
- Fatigue
- Diarrhea
- Nausea
- Rash
- Pneumonitis
Key clinical trials
- Comparison of SYN023 to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies (PHASE2)
- SYN023 With Rabies Vaccine in Healthy Pediatric Subjects (PHASE1)
- Real World Evidence Study of SYN023 in Children Exposed to Rabies
- A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety (PHASE3)
- A Bridging Study of the SYN023 on Healthy Adult Subjects (PHASE1, PHASE2)
- A Comparison of the Safety, PD and PK of a Single Dose of SYN023 Administered With Licensed Rabies Vaccines (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SYN023 CI brief — competitive landscape report
- SYN023 updates RSS · CI watch RSS
- Synermore Biologics Co., Ltd. portfolio CI